2023-2024流感监测年度中国大陆流行的季节性流感病毒对神经氨酸酶抑制剂和巴洛沙韦的敏感性  

Susceptibility of Seasonal Influenza Viruses to Neuraminidase Inhibitors and Baloxavir During the 2023-2024 Influenza Season in Chinese Mainland

作　　者：隗合江[1] 李希妍[1] 成艳辉[1] 曾晓旭[1] 谢怡然[1] 唐静[1] 邹淑梅[1] 董丽波[1] 肖宁[1] 李明泽 王大燕[1] 黄维娟[1] WEI Hejiang;LI Xiyan;CHENG Yanhui;ZENG Xiaoxu;XIE Yiran;TANG Jing;ZOU Shumei;DONG Libo;XIAO Ning;LI Mingze;WANG Dayan;HUANG Weijuan(Chinese National Influenza Center,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Key Laboratory for Medical Virology,National Health Commission,Beijing 102206,China)

机构地区：[1]中国疾病预防控制中心病毒病预防控制所、国家流感中心,国家卫生健康委员会医学病毒和病毒病重点实验室,北京102206

出　　处：《病毒学报》2024年第6期1255-1262,共8页Chinese Journal of Virology

基　　金：国家重点研发计划(项目号:2022YFF1203201),题目:病毒变异演化预测与预警技术基础体系建立。

摘　　要：为了解我国大陆流行的季节性流感病毒对抗流感病毒药物的敏感性,本文对2023-2024流感监测年度分离的季节性流感病毒进行了神经氨酸酶抑制剂和巴洛沙韦的耐药检测。基于表型方法检测的5341株季节性流感毒株中,9株A(H1N1)pdm09亚型对Oseltamivir敏感高度降低,NA基因上有H275Y位点的变异;2株B/Victoria系对Oseltamivir和Zanamivir敏感性均降低,NA基因上分别有I348T和D197N位点的变异。基于基因型方法检测的1207株季节性流感毒株中,1株A(H1N1)pdm09亚型在PA基因上有K34R和E198K位点的变异,2株A(H3N2)亚型在PA基因上有L28P位点的变异,提示对巴洛沙韦的敏感性降低。因此,上述监测数据表明2023-2024年我国大陆流行的季节性流感病毒总体上对神经氨酸酶抑制剂和巴洛沙韦敏感,这两类药物依然是治疗流感病毒感染的适当选择,而密切监测病毒对抗病毒药物的敏感性是必要的。To evaluate the susceptibility of seasonal influenza viruses circulating in mainland of China to antiviral drugs,this study tested seasonal influenza viruses isolated during the 2023-2024 influenza season for resistance to neuraminidase inhibitors and Baloxavir.Of the 5,341 seasonal influenza strains analyzed using phenotypic methods,nine A(H1N1)pdm09 strains exhibited highly reduced susceptibility to Oseltamivir,all carrying the NA-H275Y amino acid substitution.Additionally,two B/Victoria lineage strains showed reduced susceptibility to both Oseltamivir and Zanamivir,with NA-I348T or NA-D197N substitutions,respectively.Of the 1,207seasonal influenza viruses assessed through genotypic analysis,one A(H1N1)pdm09 strain had dual PA-K34R and PA-E198K substitutions,and two A(H3N2)strains carried a PA-L28P substitution,indicating potential reduced susceptibility to Baloxavir.Overall,the findings suggest that seasonal influenza viruses circulating in mainland of China during the 2023-2024 influenza season remain generally sensitive to neuraminidase inhibitors and Baloxavir,making these drugs suitable options for treating influenza infections.However,continued surveillance of antiviral susceptibility is essential.

关 键 词：季节性流感病毒 神经氨酸酶抑制剂 巴洛沙韦 IC50值 敏感性 

分 类 号：R373.1[医药卫生—病原生物学]